UK markets open in 20 minutes

NIKKEI 225
39,069.68
+282.30(+0.73%)
HANG SENG
19,663.12
+109.51(+0.56%)
CRUDE OIL
80.28
+0.22(+0.27%)
GOLD FUTURES
2,445.50
+28.10(+1.16%)
DOW
40,003.59
+134.19(+0.34%)
Bitcoin GBP
52,751.52
-10.01(-0.02%)

Neuren Pharmaceuticals Limited (NEU.AX)

ASX - ASX Delayed price. Currency in AUD

Add to watchlist

21.01

-0.08

(-0.38%)

At close: 04:10PM AEST

Loading interactive chart…

Simply Wall St.
Are Robust Financials Driving The Recent Rally In Neuren Pharmaceuticals Limited's (ASX:NEU) Stock?
Most readers would already be aware that Neuren Pharmaceuticals' (ASX:NEU) stock increased significantly by 22% over...
Simply Wall St.
An Intrinsic Calculation For Neuren Pharmaceuticals Limited (ASX:NEU) Suggests It's 44% Undervalued
Key Insights The projected fair value for Neuren Pharmaceuticals is AU$43.02 based on 2 Stage Free Cash Flow to Equity...
PR Newswire
Neuren Phase 2 trial shows significant improvements in Phelan-McDermid syndrome
Neuren Pharmaceuticals (ASX: NEU) today announced top-line results from its Phase 2 clinical trial of NNZ-2591 in children with Phelan-McDermid syndrome (PMS). Significant improvement was observed by both clinicians and caregivers from treatment, across multiple efficacy measures. Improvements were consistently seen across many of the core PMS characteristics. PMS has severe quality of life impacts for those living with the syndrome, as well as parents and siblings. There are no approved treatme